MCID: SPN040
MIFTS: 42

Spinal Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Spinal Cancer

MalaCards integrated aliases for Spinal Cancer:

Name: Spinal Cancer 12 15
Spinal Cord Neoplasms 44 73
Spinal Cord Neoplasm 12 76
Spinal Neoplasms 44 73
Malignant Tumor of the Spinal Cord 12
Tumor of the Spinal Cord 12
Intraspinal Neoplasm 73
Spinal Cord--Cancer 73
Spinal Cord Cancer 12
Spinal Cord Tumors 54
Tumors Spinal Cord 55
Intraspinal Tumor 12
Spinal Cord Tumor 29
Spinal Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5612
ICD10 33 C72.0
ICD9CM 35 192.2
NCIt 50 C3381 C3572

Summaries for Spinal Cancer

NINDS : 54 Tumors of the brain and spinal cord are abnormal growths of tissue found inside the skull or the bony spinal column.  The brain and spinal cord are the primary components of the central nervous system (CNS). Benign tumors are noncancerous, and malignant tumors are cancerous. The CNS is housed within rigid, bony quarters (i.e., the skull and spinal column), so any abnormal growth, whether benign or malignant, can place pressure on sensitive tissues and impair function. Tumors that originate in the brain or spinal cord are called primary tumors. Most primary tumors are caused by out-of-control growth among cells that surround and support neuron, specific genetic disease (such as neurofibromatosis type 1 and tuberous sclerosis), or from exposure to radiation or cancer-causing chemicals. Metastatic, or secondary, tumors in the CNS are caused by cancer cells that break away from a primary tumor located in another region of the body. Tumors can place pressure on sensitive tissues and impair function..Symptoms of brain tumors include headaches, seizures, nausea and vomiting, poor vision or hearing, changes in behavior, unclear thinking, and unsteadiness.  Spinal cord tumor symptoms include pain, numbness, and paralysis. Diagnosis is made after a neurological examination, special imaging techniques (computed tomography, and magnetic resonance imaging, positron emission tomography), laboratory tests, and a biopsy (in which a sample of tissue is taken from a suspected tumor and examined).

MalaCards based summary : Spinal Cancer, also known as spinal cord neoplasms, is related to spinal meningioma and spinal cord glioma. An important gene associated with Spinal Cancer is GFAP (Glial Fibrillary Acidic Protein). The drugs Etoposide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the spinal cord, spinal cord and brain, and related phenotype is Increased proliferation.

Disease Ontology : 12 A central nervous system cancer that is located in the spinal cord. It is mostly formed from metastases from primary cancers elsewhere (commonly breast, prostate, and lung cancer).

Wikipedia : 76 Spinal tumors are neoplasms located in the spinal cord. Extradural tumors are more common than... more...

Related Diseases for Spinal Cancer

Diseases related to Spinal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 spinal meningioma 30.3 CYP4F22 FAT2 HSF4 NF2
2 spinal cord glioma 30.0 HOXB13 NRXN2 TP53
3 malignant peripheral nerve sheath tumor 28.6 NF2 TP53
4 childhood spinal cord tumor 11.1
5 spinal cord lymphoma 10.7
6 intraventricular meningioma 10.6 GFAP NF2
7 cornea cancer 10.6 GFAP NF2
8 rhabdoid meningioma 10.6 GFAP NF2
9 benign ependymoma 10.6 GFAP NF2
10 plexiform schwannoma 10.6 GFAP NF2
11 atypical neurofibroma 10.6 GFAP NF2
12 anaplastic ependymoma 10.6 GFAP NF2
13 tanycytic ependymoma 10.6 GFAP NF2
14 cerebellopontine angle tumor 10.5 GFAP NF2
15 neurilemmoma 10.4 GFAP NF2
16 ependymoma 10.4 GFAP NF2
17 neuroma 10.4 GFAP NF2
18 myxopapillary ependymoma 10.3 GFAP HOXB13
19 hemangioblastoma 10.1
20 frontal convexity meningioma 10.1 GFAP TP53
21 gliofibroma 10.1 GFAP TP53
22 protoplasmic astrocytoma 10.1 GFAP TP53
23 cellular ependymoma 10.1 GFAP TP53
24 central nervous system primitive neuroectodermal neoplasm 10.1 GFAP TP53
25 cerebral neuroblastoma 10.1 GFAP TP53
26 mixed glioma 10.1 GFAP TP53
27 ependymoblastoma 10.1 GFAP TP53
28 cerebral ventricle cancer 10.1 GFAP TP53
29 cerebrum cancer 10.1 GFAP TP53
30 supratentorial cancer 10.1 GFAP TP53
31 olfactory groove meningioma 10.1 NF2 TP53
32 fibrillary astrocytoma 10.1 GFAP TP53
33 pleomorphic xanthoastrocytoma 10.1 GFAP TP53
34 gliomatosis cerebri 10.0 GFAP TP53
35 hemangiopericytoma, malignant 10.0
36 papilloma of choroid plexus 10.0 GFAP TP53
37 anterior cranial fossa meningioma 10.0 NF2 TP53
38 spinal cord astrocytoma 10.0 GFAP TP53
39 choroid plexus cancer 10.0 GFAP TP53
40 necrotizing sialometaplasia 10.0 GFAP TP53
41 cystic teratoma 10.0 GFAP TP53
42 cerebellar liponeurocytoma 10.0 GFAP TP53
43 small cell sarcoma 10.0 NF2 TP53
44 medullomyoblastoma 10.0 GFAP TP53
45 brain glioma 10.0 GFAP TP53
46 adult medulloblastoma 10.0 GFAP TP53
47 juvenile pilocytic astrocytoma 10.0 GFAP TP53
48 optic nerve neoplasm 10.0 NF2 TP53
49 optic nerve glioma 10.0 GFAP TP53
50 giant cell glioblastoma 9.9 GFAP TP53

Graphical network of the top 20 diseases related to Spinal Cancer:



Diseases related to Spinal Cancer

Symptoms & Phenotypes for Spinal Cancer

GenomeRNAi Phenotypes related to Spinal Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

Drugs & Therapeutics for Spinal Cancer

Drugs for Spinal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3,Phase 1,Phase 2,Not Applicable 33419-42-0 36462
2
Cisplatin Approved Phase 3,Phase 1 15663-27-1 84093 441203 2767
3
Dacarbazine Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 4342-03-4 5351166
4
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
5
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
6
Minocycline Approved, Investigational Phase 2, Phase 3 10118-90-8 5281021
7
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
8
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
9
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 85622-93-1 5394
10
Lomustine Approved, Investigational Phase 3,Phase 2 13010-47-4 3950
11
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
12
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
14
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
15
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
16
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
18
Isophosphamide mustard Phase 3,Phase 1,Phase 2 0
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 glucocorticoids Phase 3,Phase 1
21 Folic Acid Antagonists Phase 3
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
23 Hormone Antagonists Phase 3,Phase 2,Phase 1
24 Dermatologic Agents Phase 3,Phase 1,Phase 2
25 Nucleic Acid Synthesis Inhibitors Phase 3
26 Hormones Phase 3,Phase 2,Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
28 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
29 Vitamin B Complex Phase 3
30 Etoposide phosphate Phase 3,Phase 1,Phase 2,Not Applicable
31 Immunosuppressive Agents Phase 3,Phase 1
32 Anti-Infective Agents Phase 2, Phase 3,Phase 1
33 Anti-Inflammatory Agents Phase 3,Phase 1
34 Antirheumatic Agents Phase 3,Phase 1
35 Antimetabolites Phase 3
36 Antimetabolites, Antineoplastic Phase 3
37 Antimitotic Agents Phase 3,Phase 1,Phase 2,Not Applicable
38 Calcium, Dietary Phase 3
39 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
42 Dexamethasone acetate Phase 3,Phase 1 1177-87-3
43 Mitogens Phase 2, Phase 3
44 Adrenocorticotropic Hormone Phase 3
45 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
46 Corticotropin-Releasing Hormone Phase 3
47 Histone Deacetylase Inhibitors Phase 2, Phase 3,Phase 1
48 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
49 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
50 Endothelial Growth Factors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
2 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
4 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
5 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
6 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
7 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
8 Cyberknife Precision Radiation Delivery System for Tumors of the Spine Completed NCT00185666 Phase 1, Phase 2
9 A Phase I/II Study of the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
10 Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma Completed NCT00124657 Phase 1, Phase 2 Erlotinib hydrochloride
11 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma Completed NCT00028795 Phase 2 temozolomide
12 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
13 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
14 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2 Axitinib
15 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
16 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
17 Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
18 Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS) Active, not recruiting NCT00508443 Phase 1, Phase 2
19 Evaluation of Single Session Stereotactic Body Radiotherapy Active, not recruiting NCT00492817 Phase 1, Phase 2
20 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas Active, not recruiting NCT00100802 Phase 2 lomustine;temozolomide
21 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
22 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
23 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
24 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
25 Photodynamic Therapy for the Treatment of Vertebral Metastases Completed NCT02464761 Phase 1 Visudyne
26 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
27 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
28 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
29 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
30 Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Completed NCT00107458 Phase 1 valproic acid
31 SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
32 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
33 Intra-arterial Chemotherapy for Spinal Metastases Recruiting NCT01637766 Phase 1 Melphalan (intra-arterial infusion)
34 Indocyanine Green for Central Nervous System Tumors, Tumor Glow Enrolling by invitation NCT03262636 Phase 1 Indocyanine Green
35 Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer Terminated NCT01407341 Phase 1
36 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
37 MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer Terminated NCT00572182 Phase 1 MK-0752
38 Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment Withdrawn NCT00458744 Phase 1 talotrexin
39 Impact of Balanced Slat Colloid HES 130/0.42 on Coagulation Profiles in Patients Undergoing Spinal Cord Tumor Surgery Unknown status NCT01921595 Not Applicable
40 Establishment of a Brain and Spinal Tumor Tissue Bank Unknown status NCT00686387
41 The Development of a Vertebra Localizing Aid Medical Device Unknown status NCT02603874 Not Applicable
42 Spinal Motor Evoked Potentials in Brain Surgery Unknown status NCT02402075
43 Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery Unknown status NCT02527304 Not Applicable
44 Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer Unknown status NCT00349024 Not Applicable polyvinylpyrrolidone-sodium hyaluronate gel
45 Direct Injection of Alcohol for the Treatment of Spinal Tumors Completed NCT00001417
46 Alternative Treatment of Giant Spinal Schwannomas Completed NCT02494622
47 Development of the MDASI-Spine Tumor Module Completed NCT00430872
48 Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord Completed NCT00631670 Not Applicable
49 Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas Completed NCT00276640 Not Applicable vincristine, carboplatin;vincristine, carboplatin, etoposide
50 A Clinical Study of a Spine Fusion System in Vertebral Body Fusion Surgery Completed NCT02252185 Not Applicable

Search NIH Clinical Center for Spinal Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: spinal cord neoplasms

Genetic Tests for Spinal Cancer

Genetic tests related to Spinal Cancer:

# Genetic test Affiliating Genes
1 Spinal Cord Tumor 29

Anatomical Context for Spinal Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Spinal Cancer:

19
The Spinal Cord

MalaCards organs/tissues related to Spinal Cancer:

41
Spinal Cord, Brain, Testes, Prostate, Lung, Bone, Endothelial

Publications for Spinal Cancer

Articles related to Spinal Cancer:

# Title Authors Year
1
Surgical vertebral body cementoplasty as spinal cancer metastasis management. ( 25548834 )
2014
2
An in vivo mouse model of intraosseous spinal cancer causing evolving paraplegia. ( 23955595 )
2013
3
A study investigating the validity of modified Tokuhashi score to decide surgical intervention in patients with metastatic spinal cancer. ( 22899107 )
2013
4
Thoracic spinal iophendylate-induced arachnoiditis mimicking an intramedullary spinal cord neoplasm. Case report. ( 18312083 )
2008
5
Survival analysis of 459 adult patients with primary spinal cancer in England and Wales: a population-based study. ( 17210300 )
2007
6
Part I: spinal-cord neoplasms-intradural neoplasms. ( 17196509 )
2007
7
Schistosomal myelopathy mimicking spinal cord neoplasm. ( 16051574 )
2005
8
[Spinal deformations as a cause for the clinical signs of spinal cord neoplasm]. ( 12852003 )
2003
9
Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. ( 8893440 )
1996

Variations for Spinal Cancer

Cosmic variations for Spinal Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5702591 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 10
2 COSM28746 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 10
3 COSM28747 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 10
4 COSM28748 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 10
5 COSM28749 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 10
6 COSM28750 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 10
7 COSM5702574 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 10
8 COSM5702592 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 10

Expression for Spinal Cancer

Search GEO for disease gene expression data for Spinal Cancer.

Pathways for Spinal Cancer

GO Terms for Spinal Cancer

Cellular components related to Spinal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 8.62 GFAP NF2

Biological processes related to Spinal Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to wounding GO:0009611 8.96 GFAP HOXB13
2 positive regulation of cell differentiation GO:0045597 8.62 HSF4 NF2

Sources for Spinal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....